HCN Oncology Year-in-Review: MelanomaDecember 21, 2021 | Oncology Dermatology LEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab Lead author of the study, Dr. Ana Maria Arance, who presented the results over the summer at the ASCO Annual Meeting, commented: “With additional follow-up, lenvatinib plus pembrolizumab continues to show clinically meaningful, durable responses in patients with advanced melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given alone or in combination. These data support lenvatinib plus pembrolizumab as a potential regimen for this population of high unmet need.” Read full article Dermatology Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma Presented at the virtual American Society of Clinical Oncology (ASCO) annual meeting, the findings from the S1404 clinical trial demonstrated that, although the PD-1 inhibitor pembrolizumab (Keytruda) came up short in both the intent-to-treat (ITT) population and PD-L1-positive subgroup, relapse-free survival (RFS) was significantly improved compared with those who received either ipilimumab (Yervoy) or high-dose interferon. Read full article Dermatology Immunotherapy Combination Shows Benefit for Patients w. Advanced Melanoma, Phase 3 Trial Shows The results of the trial, known as the RELATIVITY-047 study, were presented at the virtual ASCO Annual Meeting that took place June 4-8, 2021. The Dana-Farber Cancer Institute Investigators who co-led the study were thrilled to present that, despite PD-1 blocker nivolumab revolutionizing the treatment of patients with advanced melanoma, this fixed-dose combination of nivolumab and LAG-3 target relatlimab holds the cancer in check significantly longer than nivolumab alone. Read full article Dermatology Results of KEYNOTE-716 Trial May ‘Level the Playing Field Against Melanoma’ The results, presented during the virtual ESMO Congress 2021, will substantially change the population of patients with melanoma who undergo treatment in the adjuvant setting, according to Jason J. Luke, MD: “Patients with stage IIB/C melanoma have similar rates of recurrence and melanoma specific survival to those with stage IIIA/B disease. Despite this, adjuvant anti-PD-1 immunotherapy has only been available in standard practice for stage III disease. The results of KEYNOTE-716 will facilitate access to anti-PD-1 for stage IIB/C patients and, in a sense, level the playing field against melanoma.” Read full article Dermatology Anuric Kidney Failure in a Patient With Metastatic Melanoma Test your knowledge on this case study from JAMA Oncology! Full text available with registration, or you can access the Clinical Challenge from your institution. Good luck! Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS